Maxigen BiotechTPE:1783 +0.52%87 Quick Ratio is 2.93 as of Dec. 2025, which is 27% below its 10-year median of 4.03. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$61.07 (Significantly Undervalued). Among 855 Medical Devices & Instruments companies, Maxigen Biotech ranks better than 67.25% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Maxigen Biotech's quick ratio for the quarter that ended in Dec. 2025 was 2.93.
Maxigen Biotech has a quick ratio of 2.93. It generally indicates good short-term financial strength.
The historical rank and industry rank for Maxigen Biotech's Quick Ratio or its related term are showing as below:
TPE:1783'
s Quick Ratio Range Over the Past 10 Years
Min: 1.71 Med: 4.03 Max: 6.07
Current: 2.93
During the past 13 years, Maxigen Biotech's highest Quick Ratio was 6.07. The lowest was 1.71. And the median was 4.03.
TPE:1783's Quick Ratio is ranked better than 67.25% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 1.86
vs TPE:1783: 2.93
Maxigen Biotech (TPE:1783) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Maxigen Biotech Quick Ratio Related Terms
Maxigen Biotech Quick Ratio Historical Data
* Premium members only.
The historical data trend for Maxigen Biotech's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1783 vs ISRG, BDX, MDLN: Quick Ratio Comparison
For the Medical Instruments & Supplies subindustry, Maxigen Biotech's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maxigen Biotech Quick Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Maxigen Biotech's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Maxigen Biotech's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maxigen Biotech (TPE:1783) has a Quick Ratio of 2.93 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Maxigen Biotech and its competitors. This is 27% below median its historical median of 4.03. Over the past decade, Maxigen Biotech's Quick Ratio has ranged from 1.71 to 6.07. According to the industry distribution chart, Maxigen Biotech ranks #280 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 32.7%.
Is Maxigen Biotech's Quick Ratio too high?
Maxigen Biotech's current Quick Ratio of 2.93 is 27% below median its 10-year median of 4.03. Over the past 10 years, this metric has ranged from a low of 1.71 to a high of 6.07. The Medical Devices & Instruments industry median Quick Ratio is 1.86. Maxigen Biotech's value of 2.93 is 57.5% above this industry median. Based on the distribution chart, Maxigen Biotech ranks #280 out of 855 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's Quick Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Maxigen Biotech ranks #280 out of 855 companies for Quick Ratio. This puts Maxigen Biotech in the upper half of its industry. The industry median Quick Ratio is 1.86. Maxigen Biotech's value of 2.93 is 57.5% above this benchmark. Historically, Maxigen Biotech's own Quick Ratio has ranged from 1.71 to 6.07 over the past decade. While the company's 10-year median is 4.03 vs. the industry median of 1.86, Maxigen Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Devices & Instruments company?
The median Quick Ratio among Medical Devices & Instruments companies is 1.86, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maxigen Biotech's current Quick Ratio of 2.93 is 57.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Maxigen Biotech and its competitors. For the Medical Devices & Instruments industry, the median Quick Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maxigen Biotech's current Quick Ratio is 2.93, which is 27% below median its own 10-year median of 4.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$61.07, compared to a current price of NT$39.00 — trading 36.1% below its estimated fair value. The current Quick Ratio is 2.93, which is 27% below median its 10-year median of 4.03 and 57.5% above the Medical Devices & Instruments industry median of 1.86. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current Quick Ratio is 2.93 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maxigen Biotech (TPE:1783) Overvalued in 2026?
Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued.
The current stock price of NT$39.00 is trading 36.1% below its estimated GF Value™ of NT$61.07.
GuruFocus considers Maxigen Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1783:
Quick Ratio: 2.93 (27% below median its 10-year median of 4.03)
GF Value™: NT$61.07 vs. price of NT$39.00 (36.1% below fair value)
Industry Position: 57.5% above the Medical Devices & Instruments median (#280 of 855)
No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score
Get the complete analysis for TPE:1783
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1783 has been successfully added to your 
